Mathias Schmidt has spent over 25 years in the (Bio)pharmaceuticals Industry in various positions including research, preclinical and clinical development, business development, global business expansion and executive management. He has been in with JCR Pharmaceuticals since 2020 where he has been serving in multiple different functions in executive management, business internationalization, business development and clinical development. Prior to joining JCR, he has been (and still is) President and CEO of ArmaGen, Inc. and chaperoned JCR’s acquisition of ArmaGen. Previous positions include Takeda Pharmaceuticals, Nycomed, Altana Pharma and ASTA Medica. Mathias received his master’s degree from the University of Stuttgart, a Ph.D. in tumor biology from the University of Freiburg and the venia legendi in Pharmacology from the University of Konstanz where he has been lecturing Disease Biology for many years. Earlier in his career Mathias worked at several cancer hospitals in Germany and the United States.

Mathias is driven by a strong sense of purpose to create a better tomorrow for the patients we aspire to serve based on the recognition that all human life has equal value and that most of the diseases people suffer from are not a choice of lifestyle.